Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2NET 2Endocrine 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 491Lung Neoplasms 208Adenocarcinoma of Lung 49Small Cell Lung Carcinoma 34Neoplasms 31Adenocarcinoma, Bronchiolo-Alveolar 25Neoplasm Metastasis 20Breast Neoplasms 20Ovarian Neoplasms 19Colorectal Neoplasms 16Carcinoma 14Squamous Cell Carcinoma of Head and Neck 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Melanoma 13Carcinoma, Ovarian Epithelial 12Stomach Neoplasms 11Carcinoma, Renal Cell 9Head and Neck Neoplasms 8Respiratory Tract Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Endometrial Neoplasms 7Thoracic Neoplasms 6Pleural Effusion, Malignant 6Lung Diseases 6Esophageal Neoplasms 6Colonic Neoplasms 6Carcinoma, Squamous Cell 6Adenocarcinoma 6Non-Squamous Non-Small Cell Lung Cancer 5

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2Everolimus 2Carboplatin 2tislelizumab 1taxane 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1olaparib 1liposomal doxorubicin 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1RRx-001 1Quality of Life 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Paclitaxel × Thoracic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT01317615 2016-03-30

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Novartis

Phase 4 Completed
49 enrolled 11 charts
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Large Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡